Page last updated: 2024-10-27

gliclazide and Body-Weight Trajectory

gliclazide has been researched along with Body-Weight Trajectory in 1 studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Body-Weight Trajectory: A general pattern of body weight gain or loss over many years. Weight change trajectory is influenced by several determinants in children and adults.

Research Excerpts

ExcerptRelevanceReference
"Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes."2.94The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lee, AK1
Woodward, M1
Wang, D1
Ohkuma, T1
Warren, B1
Sharrett, AR1
Williams, B1
Marre, M1
Hamet, P1
Harrap, S1
Mcevoy, JW1
Chalmers, J1
Selvin, E1

Trials

1 trial available for gliclazide and Body-Weight Trajectory

ArticleYear
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
    The Journal of clinical endocrinology and metabolism, 2020, 01-01, Volume: 105, Issue:1

    Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin

2020